Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / irb-submission-strategy-memo.docx
irb-submission-strategy-memo.docx
Parties
Harkness LLP
Solstice Biomedical Devices Ltd
Solstice Biomedical Inc
Pinnacle Regulatory Consulting Group LLC
Clearwater Institutional Review Board LLC
Veltrano Clinical Research Organization Inc
Meridian Conformity Assessment GmbH
Atlas Underwriting Partners Ltd
Dates
May 19, 2025
September 15, 2025
September 1, 2025
August 14, 2025
April 30, 2026
July 21, 2025
June 30, 2025
November 14, 2019
July 7, 2025
July 14, 2025
Amounts
$25,000,000
$50,000,000
$3,000
$7,500
Obligations
This memorandum is intended to serve as a comprehensive reference for the Solstice team, coordinating counsel, and regulatory consultants as the parties prepare for the initial IRB submission, and it identifies the critical-path activities that must be completed to support a target study commencement date of September 15, 2025
To achieve this milestone, IRB approval must be obtained no later than September 1, 2025, allowing a two-week buffer for the completion of site initiation visits at all six clinical sites
Calderwood & Harkness notes that each of the six clinical sites will need to enter into a reliance agreement or authorization agreement with Clearwater IRB, pursuant to which the site agrees to rely on Clearwater IRB's review and approval in lieu of review by the site's own local IRB (if any)
However, even IDE-exempt studies must comply with certain provisions of Part 812, including the requirements for informed consent (§ 812
The sponsor must document this determination in writing, along with the supporting rationale, and must submit the determination to the IRB as part of the initial review package
The IRB must make its own independent assessment of whether the investigation presents a significant risk or a non-significant risk